TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04757116: Post-Market Study to Assess iTind Safety in Comparison to UroLift

Sponsor: Olympus Corporation of the Americas · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 256 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$2,191,200

Rescue Site Savings

+$1,460,800

Unlock Full NCT04757116 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04757116 Rescue Dossier →